Strengthened collaboration with European biotech customer who extends their service and support agreement for another 12 months.
The customer develops therapeutic antibodies against cancer and uses Attana's cell-based technology to test and verify its drug candidates in as physically similar conditions as possible. As the target receptors are membrane proteins in the cancer cells, Attana's technology is the only technology that can perform this label-free (ie without fluorescence or similar tags). The alternatives with labeled molecules have generated results with poorer agreement with in-vivo experiments. Attana's technology speeds up and increases the precision of their development process and reduces their